开发APOBEC3B抑制剂:最近的进展和前景
Wenjie Zhang1, Yuhang Wang1, Cheng Jiang1
1School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, PR China; Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Bioorganic chemistry
|September 30, 2025
概括
阿波蛋白B mRNA编辑催化多类3B (A3B) 是病毒免疫和瘤突变的关键参与者. 针对A3B的抑制剂显示出克服瘤耐药性的承诺.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 阿波蛋白B mRNA编辑催化型多类3B (A3B) 是一种参与病毒免疫的cytidine deaminase.
- A3B有助于瘤相关突变,并且在各种癌症中异常表达.
- 它在促进瘤生长,迁移和耐药性方面的作用使其成为治疗点.
研究的目的:
- 审查A3B的结构,生物功能和疾病相关性.
- 要总结目前关于A3B抑制剂的研究.
- 讨论A3B抑制剂的设计要求和作用机制.
主要方法:
- 关于A3B结构,功能和疾病相关性的文献综述.
- 报告的A3B抑制剂的系统摘要.
- 对抑制剂设计原理和作用模式的分析.
主要成果:
- 强调了A3B在病毒防御和瘤发生中的双重作用.
- 异常的A3B表达与侵袭性瘤表型和耐药性相关.
- 橄核酸和全抑制剂显示出有前途的治疗潜力.
结论:
- A3B是癌症进展和耐药性的重要因素.
- 针对A3B提供了癌症治疗的潜在策略.
- 选择性A3B抑制剂的进一步开发是有必要的.
关键词:
A3B 抑制剂的使用APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B APOBEC3B艾洛斯特抑制剂 艾洛斯特抑制剂药物发现 药物发现有氧核酸类的更多相关视频
相关概念视频
Microorganisms in Medicine and Therapeutics
982
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
982
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321


